Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
• Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
• Willing and able to comply with clinic visits and study-related procedures
• Provide signed informed consent
Locations
United States
California
Beverly Hills, CA
NOT_YET_RECRUITING
Beverly Hills
Pennsylvania
Erie, PA
RECRUITING
Erie
Texas
Bellaire, TX
NOT_YET_RECRUITING
Bellaire
McAllen, TX
RECRUITING
Mcallen
The Woodlands, TX
NOT_YET_RECRUITING
The Woodlands
Contact Information
Primary
Kim Reed, OD, FAAO
info@eyconis.com
1-866-392-6647
Backup
Karen Chu, MS
info@eyconis.com
1-866-392-6647
Time Frame
Start Date: 2026-05-19
Estimated Completion Date: 2028-05
Participants
Target number of participants: 30
Treatments
Experimental: EYC-0305 Dose Level 1
Experimental: EYC-0305 Dose Level 2
Experimental: EYC-0305 Dose Level 3
Experimental: EYC-0305 Dose Level 4
Related Therapeutic Areas
Sponsors
Leads: Eyconis INC.